U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma

MedGen UID:
1663268
•Concept ID:
C4744834
•
Neoplastic Process

Definition

The reemergence of primary peritoneal low grade serous adenocarcinoma after a period of remission. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRecurrent Primary Peritoneal Low Grade Serous Adenocarcinoma

Professional guidelines

PubMed

Contemporary primary treatment of women with stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC): Determinants of relapse and disease-free survival.
Gershenson DM, Cobb LP, Westin SN, Zhang Y, Jazaeri A, Malpica A, Sun CC
Gynecol Oncol 2022 Nov;167(2):139-145. Epub 2022 Sep 20 doi: 10.1016/j.ygyno.2022.09.005. PMID: 36137845

Recent clinical studies

Etiology

Prognostic value of HE4 in advanced-stage, high-grade serous ovarian cancer: Analysis of HE4 kinetics during NACT, predicting surgical outcome and recurrence in comparison to CA125.
AlSomairi A, Himayda S, Altelmesani A, Lee YJ, Lee JY
Gynecol Oncol 2024 Feb;181:155-161. Epub 2024 Jan 3 doi: 10.1016/j.ygyno.2023.12.021. PMID: 38176127
Chemotherapy response in low-grade serous ovarian carcinoma at a comprehensive cancer center: Readdressing the roles of platinum and cytotoxic therapies.
Manning-Geist BL, Kahn RM, Nemirovsky D, Girshman J, Laibangyang A, Gordhandas S, Iasonos A, Chui MH, Long Roche K, Zivanovic O, Chi DS, Aghajanian C, Grisham RN
Cancer 2023 Jul 1;129(13):2004-2012. Epub 2023 Mar 23 doi: 10.1002/cncr.34753. PMID: 36951509Free PMC Article
Contemporary primary treatment of women with stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC): Determinants of relapse and disease-free survival.
Gershenson DM, Cobb LP, Westin SN, Zhang Y, Jazaeri A, Malpica A, Sun CC
Gynecol Oncol 2022 Nov;167(2):139-145. Epub 2022 Sep 20 doi: 10.1016/j.ygyno.2022.09.005. PMID: 36137845
Genomic catastrophe, the peritoneal cavity and ovarian cancer prevention.
Yoon JY, Chapel DB, Goebel E, Qian X, Mito JK, Horowitz NS, Miron A, Soong TR, Xian W, Crum CP
J Pathol 2022 Jul;257(3):255-261. Epub 2022 Apr 18 doi: 10.1002/path.5891. PMID: 35238033
MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.
Monk BJ, Grisham RN, Banerjee S, Kalbacher E, Mirza MR, Romero I, Vuylsteke P, Coleman RL, Hilpert F, Oza AM, Westermann A, Oehler MK, Pignata S, Aghajanian C, Colombo N, Drill E, Cibula D, Moore KN, Christy-Bittel J, Del Campo JM, Berger R, Marth C, Sehouli J, O'Malley DM, Churruca C, Boyd AP, Kristensen G, Clamp A, Ray-Coquard I, Vergote I
J Clin Oncol 2020 Nov 10;38(32):3753-3762. Epub 2020 Aug 21 doi: 10.1200/JCO.20.01164. PMID: 32822286Free PMC Article

Diagnosis

Prognostic value of HE4 in advanced-stage, high-grade serous ovarian cancer: Analysis of HE4 kinetics during NACT, predicting surgical outcome and recurrence in comparison to CA125.
AlSomairi A, Himayda S, Altelmesani A, Lee YJ, Lee JY
Gynecol Oncol 2024 Feb;181:155-161. Epub 2024 Jan 3 doi: 10.1016/j.ygyno.2023.12.021. PMID: 38176127
Chemotherapy response in low-grade serous ovarian carcinoma at a comprehensive cancer center: Readdressing the roles of platinum and cytotoxic therapies.
Manning-Geist BL, Kahn RM, Nemirovsky D, Girshman J, Laibangyang A, Gordhandas S, Iasonos A, Chui MH, Long Roche K, Zivanovic O, Chi DS, Aghajanian C, Grisham RN
Cancer 2023 Jul 1;129(13):2004-2012. Epub 2023 Mar 23 doi: 10.1002/cncr.34753. PMID: 36951509Free PMC Article
Contemporary primary treatment of women with stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC): Determinants of relapse and disease-free survival.
Gershenson DM, Cobb LP, Westin SN, Zhang Y, Jazaeri A, Malpica A, Sun CC
Gynecol Oncol 2022 Nov;167(2):139-145. Epub 2022 Sep 20 doi: 10.1016/j.ygyno.2022.09.005. PMID: 36137845
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022.
Armstrong DK, Alvarez RD, Backes FJ, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Chen LM, Chitiyo VC, Cristea M, DeRosa M, Eisenhauer EL, Gershenson DM, Gray HJ, Grisham R, Hakam A, Jain A, Karam A, Konecny GE, Leath CA III, Leiserowitz G, Liu J, Martin L, Matei D, McHale M, McLean K, Miller DS, Percac-Lima S, Remmenga SW, Schorge J, Stewart D, Thaker PH, Vargas R, Hendrickson AW, Werner TL, Zsiros E, Dwyer MA, Hang L
J Natl Compr Canc Netw 2022 Sep;20(9):972-980. doi: 10.6004/jnccn.2022.0047. PMID: 36075393
The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer.
Crane EK, Sun CC, Ramirez PT, Schmeler KM, Malpica A, Gershenson DM
Gynecol Oncol 2015 Jan;136(1):25-9. Epub 2014 Nov 8 doi: 10.1016/j.ygyno.2014.11.005. PMID: 25448453Free PMC Article

Therapy

Chemotherapy response in low-grade serous ovarian carcinoma at a comprehensive cancer center: Readdressing the roles of platinum and cytotoxic therapies.
Manning-Geist BL, Kahn RM, Nemirovsky D, Girshman J, Laibangyang A, Gordhandas S, Iasonos A, Chui MH, Long Roche K, Zivanovic O, Chi DS, Aghajanian C, Grisham RN
Cancer 2023 Jul 1;129(13):2004-2012. Epub 2023 Mar 23 doi: 10.1002/cncr.34753. PMID: 36951509Free PMC Article
Contemporary primary treatment of women with stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC): Determinants of relapse and disease-free survival.
Gershenson DM, Cobb LP, Westin SN, Zhang Y, Jazaeri A, Malpica A, Sun CC
Gynecol Oncol 2022 Nov;167(2):139-145. Epub 2022 Sep 20 doi: 10.1016/j.ygyno.2022.09.005. PMID: 36137845
New therapeutic opportunities for women with low-grade serous ovarian cancer.
Moujaber T, Balleine RL, Gao B, Madsen I, Harnett PR, DeFazio A
Endocr Relat Cancer 2021 Nov 11;29(1):R1-R16. doi: 10.1530/ERC-21-0191. PMID: 34636747
MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.
Monk BJ, Grisham RN, Banerjee S, Kalbacher E, Mirza MR, Romero I, Vuylsteke P, Coleman RL, Hilpert F, Oza AM, Westermann A, Oehler MK, Pignata S, Aghajanian C, Colombo N, Drill E, Cibula D, Moore KN, Christy-Bittel J, Del Campo JM, Berger R, Marth C, Sehouli J, O'Malley DM, Churruca C, Boyd AP, Kristensen G, Clamp A, Ray-Coquard I, Vergote I
J Clin Oncol 2020 Nov 10;38(32):3753-3762. Epub 2020 Aug 21 doi: 10.1200/JCO.20.01164. PMID: 32822286Free PMC Article
Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer.
Grisham RN, Iyer G, Sala E, Zhou Q, Iasonos A, DeLair D, Hyman DM, Aghajanian C
Int J Gynecol Cancer 2014 Jul;24(6):1010-4. doi: 10.1097/IGC.0000000000000190. PMID: 24978709Free PMC Article

Prognosis

Prognostic value of HE4 in advanced-stage, high-grade serous ovarian cancer: Analysis of HE4 kinetics during NACT, predicting surgical outcome and recurrence in comparison to CA125.
AlSomairi A, Himayda S, Altelmesani A, Lee YJ, Lee JY
Gynecol Oncol 2024 Feb;181:155-161. Epub 2024 Jan 3 doi: 10.1016/j.ygyno.2023.12.021. PMID: 38176127
New therapeutic opportunities for women with low-grade serous ovarian cancer.
Moujaber T, Balleine RL, Gao B, Madsen I, Harnett PR, DeFazio A
Endocr Relat Cancer 2021 Nov 11;29(1):R1-R16. doi: 10.1530/ERC-21-0191. PMID: 34636747
MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.
Monk BJ, Grisham RN, Banerjee S, Kalbacher E, Mirza MR, Romero I, Vuylsteke P, Coleman RL, Hilpert F, Oza AM, Westermann A, Oehler MK, Pignata S, Aghajanian C, Colombo N, Drill E, Cibula D, Moore KN, Christy-Bittel J, Del Campo JM, Berger R, Marth C, Sehouli J, O'Malley DM, Churruca C, Boyd AP, Kristensen G, Clamp A, Ray-Coquard I, Vergote I
J Clin Oncol 2020 Nov 10;38(32):3753-3762. Epub 2020 Aug 21 doi: 10.1200/JCO.20.01164. PMID: 32822286Free PMC Article
The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer.
Crane EK, Sun CC, Ramirez PT, Schmeler KM, Malpica A, Gershenson DM
Gynecol Oncol 2015 Jan;136(1):25-9. Epub 2014 Nov 8 doi: 10.1016/j.ygyno.2014.11.005. PMID: 25448453Free PMC Article
Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer.
Grisham RN, Iyer G, Sala E, Zhou Q, Iasonos A, DeLair D, Hyman DM, Aghajanian C
Int J Gynecol Cancer 2014 Jul;24(6):1010-4. doi: 10.1097/IGC.0000000000000190. PMID: 24978709Free PMC Article

Clinical prediction guides

Prognostic value of HE4 in advanced-stage, high-grade serous ovarian cancer: Analysis of HE4 kinetics during NACT, predicting surgical outcome and recurrence in comparison to CA125.
AlSomairi A, Himayda S, Altelmesani A, Lee YJ, Lee JY
Gynecol Oncol 2024 Feb;181:155-161. Epub 2024 Jan 3 doi: 10.1016/j.ygyno.2023.12.021. PMID: 38176127
Chemotherapy response in low-grade serous ovarian carcinoma at a comprehensive cancer center: Readdressing the roles of platinum and cytotoxic therapies.
Manning-Geist BL, Kahn RM, Nemirovsky D, Girshman J, Laibangyang A, Gordhandas S, Iasonos A, Chui MH, Long Roche K, Zivanovic O, Chi DS, Aghajanian C, Grisham RN
Cancer 2023 Jul 1;129(13):2004-2012. Epub 2023 Mar 23 doi: 10.1002/cncr.34753. PMID: 36951509Free PMC Article
Genomic catastrophe, the peritoneal cavity and ovarian cancer prevention.
Yoon JY, Chapel DB, Goebel E, Qian X, Mito JK, Horowitz NS, Miron A, Soong TR, Xian W, Crum CP
J Pathol 2022 Jul;257(3):255-261. Epub 2022 Apr 18 doi: 10.1002/path.5891. PMID: 35238033
MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.
Monk BJ, Grisham RN, Banerjee S, Kalbacher E, Mirza MR, Romero I, Vuylsteke P, Coleman RL, Hilpert F, Oza AM, Westermann A, Oehler MK, Pignata S, Aghajanian C, Colombo N, Drill E, Cibula D, Moore KN, Christy-Bittel J, Del Campo JM, Berger R, Marth C, Sehouli J, O'Malley DM, Churruca C, Boyd AP, Kristensen G, Clamp A, Ray-Coquard I, Vergote I
J Clin Oncol 2020 Nov 10;38(32):3753-3762. Epub 2020 Aug 21 doi: 10.1200/JCO.20.01164. PMID: 32822286Free PMC Article
Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer.
Grisham RN, Iyer G, Sala E, Zhou Q, Iasonos A, DeLair D, Hyman DM, Aghajanian C
Int J Gynecol Cancer 2014 Jul;24(6):1010-4. doi: 10.1097/IGC.0000000000000190. PMID: 24978709Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...